ObsEva S.A.

Suisse

Commandez votre montre hebdomadaire ObsEva S.A.
Quantité totale PI 61
Rang # Quantité totale PI 22 789
Note d'activité PI 2/5.0    14
Rang # Activité PI 61 178
Symbole boursier
ISIN CH0346177709
Capitalisation 107M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Produits pharmaceutiques, vétéri...

Brevets

Marques

14 9
7 8
14 9
0
 
Dernier brevet 2024 - Pyrrolidine derivatives as oxyto...
Premier brevet 2014 - Pyrrolidine derivatives as oxyto...
Dernière marque 2019 - EQBRYSIS
Première marque 2013 - OBSEVA

Industrie (Classification de Nice)

Derniers inventions, produits et services

2023 Invention Pyrrolidine derivatives as oxytocin/vasopressin v1a receptors antagonists. The present invention...
2022 Invention Oral formulations of pyrrolidine derivatives. The present invention relates to solid oral formul...
2021 Invention Compositions and methods for the treatment or prevention of preterm labor. The disclosure provide...
Invention Biomarkers for oxytocin receptor antagonist therapy. The disclosure provides compositions and me...
Invention Biomarkers for oxytocin receptor antagonist therapy. The disclosure provides compositions and met...
2020 Invention Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage....
Invention Compositions and methods for the treatment of estrogen-dependent disorders. The present disclosur...
Invention Gnrh antagonists for the treatment of estrogen-dependent disorders. The present disclosure provid...
Invention Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonists. The present invention ...
2019 Invention Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis. The pre...
P/S Medical preparations for the prevention and treatment of reproductive and neuropsychiatric diseas...
P/S Medical preparations; pharmaceutical and veterinary products; sanitary preparations for medical ...
Invention Oral formulations of pyrrolidine derivatives. The present invention relates to solid oral formula...
2018 P/S Medical preparations for the prevention and treatment of reproductive and neuro-psychiatric disea...
Invention Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis. The...
Invention Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reduc...
2017 Invention Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one ...
Invention Pyrrolidine derivatives as oxytocin/vasopressin v1a receptors antagonists. The present invention ...
Invention Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal pol...
2015 Invention Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one ...
2014 Invention Pyrrolidine derivatives as oxytocin / vasopressin v1a receptors antagonists. The present inventio...
2013 P/S Medical [, ] * and * pharmaceutical, [ and veterinary ] preparations for the prevention and trea...
P/S Medical, pharmaceutical, veterinary and sanitary products; pharmaceutical and biotechnological p...